MBX Biosciences (MBX) Non-Current Assets (2023 - 2026)
MBX Biosciences (MBX) posted Non-Current Assets of $4.2 million for Q1 2026, up 15.53% sequentially from $3.6 million in Q4 2025, and up 152.42% YoY from $1.6 million in Q1 2025.
MBX Biosciences (MBX) Non-Current Assets (2023 - 2026) Analysis & Trends
MBX Biosciences has reported Non-Current Assets for 4 years, with the latest figure at $4.2 million in Q1 2026.
- Quarterly Non-Current Assets rose 152.42% year-over-year to $4.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.7 million (up 161.68% YoY) and the FY2025 annual result came in at $3.6 million, up 188.63% from the prior year.
- Non-Current Assets improved to $4.2 million in Q1 2026 per MBX's latest filing, from $3.6 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $4.2 million in Q1 2026 and troughed at $715000.0 in Q4 2023.
- A 4-year average of $2.2 million and a median of $2.0 million in 2025 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2024 and 2025: Non-Current Assets surged 74.69% in 2024, then surged 188.63% in 2025.
- Over 4 years, Non-Current Assets stood at $715000.0 in 2023, then soared by 74.69% to $1.2 million in 2024, then soared by 188.63% to $3.6 million in 2025, then rose by 15.53% to $4.2 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $4.2 million, $3.6 million, and $2.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | MBX Biosciences | 3.29 Bn | 3.29 Bn | - | 8.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.05 Mn |
| Mar 31, 2026 | 4.17 Mn |
| Dec 31, 2025 | 3.61 Mn |
| Sep 30, 2025 | 2.57 Mn |
| Jun 30, 2025 | 2.33 Mn |
| Mar 31, 2025 | 1.65 Mn |
| Dec 31, 2024 | 1.25 Mn |
| Sep 30, 2024 | 1.23 Mn |
| Dec 31, 2023 | 715,000.00 |